Queensland Health has conducted a successful early phase clinical trial of monoclonal antibody against the Hendra virus in humans.
Dr Jeanette Young, Queensland Health’s chief medical officer, told The Courier Mail that all 40 participants of the year-long trial were well and had not suffered any negative impact from the treatment.
The trial cohort comprised five groups of eight people each. Six groups were given the antibody and two were given a placebo. The subjects ranged from 18 to 65 years of age.
Dr Young went on to say that though testing had been completed in mid-June, the clinical results would be released later in the year.
“All participants remain well. No serious adverse events have occurred,” said Dr Young.
“We are now in the processes of analysing data generated from the clinical trial with results expected in late 2016.”
Clarification—This article and its original title, “Hendra vaccine could work in humans too”, incorrectly implied that horses and humans could be treated with the same vaccine. In fact, the monoclonal antibody discussed in the story is unrelated to any equine vaccine. The title and story have been amended.